The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events.
Rheum Dis Clin North Am
; 50(2): 181-199, 2024 May.
Article
in En
| MEDLINE
| ID: mdl-38670720
ABSTRACT
Immune checkpoint inhibitors (ICIs) have greatly improved survival of several cancers with historically very poor prognosis. ICIs act by stimulating the patient's own immune system to fight cancer. Simultaneously, this immune activation can lead to immune-related adverse events (irAEs), including rheumatic manifestations (Rh-irAEs). Rh-irAEs mimic primary rheumatic diseases including arthritis, polymyalgia rheumatica, myositis, vasculitis, sarcoidosis, and sicca. This article summarizes the latest evidence regarding the utility of laboratory investigations in Rh-irAEs.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Rheumatic Diseases
/
Immune Checkpoint Inhibitors
Limits:
Humans
Language:
En
Journal:
Rheum Dis Clin North Am
Journal subject:
REUMATOLOGIA
Year:
2024
Document type:
Article
Affiliation country:
Canadá